<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743414</url>
  </required_header>
  <id_info>
    <org_study_id>CP543.1007</org_study_id>
    <nct_id>NCT04743414</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1 Open-Label Study to Assess the Effect of a Strong CYP3A4 Inhibitor, Itraconazole, on the Single Dose Pharmacokinetic Profile of CTP-543 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concert Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concert Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 open-label study of the effect of itraconazole on the pharmacokinetics of&#xD;
      CTP-543 in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Actual">April 5, 2021</completion_date>
  <primary_completion_date type="Actual">March 27, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>48 hours</time_frame>
    <description>Area Under the Plasma Concentration-Time Profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf</measure>
    <time_frame>48 hours</time_frame>
    <description>Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Maximum observed concentration of drug in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Time to reach maximum observed concentration of drug in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 40 days</time_frame>
    <description>An adverse event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>CTP-543</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1, participants will receive a single oral dose of CTP-543. Following a washout period on Days 2 and 3, participants will receive a single oral dose of itraconazole on Day 4 through Day 8, with a single oral dose of CTP-543 being co-administered on Day 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-543</intervention_name>
    <description>Itraconazole in solution dosage form</description>
    <arm_group_label>CTP-543</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-smoker who has not used nicotine-containing products for at least 3 months prior&#xD;
             to the first dosing and throughout the study&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at Screening&#xD;
&#xD;
          -  Medically healthy with no clinically significant medical history, physical&#xD;
             examination, laboratory profiles, vital signs or ECGs&#xD;
&#xD;
          -  If of reproductive age, willing and able to use a medically highly effective form of&#xD;
             birth control 30 days prior to first dose, during the study and for 30 days following&#xD;
             last dose of study medication.&#xD;
&#xD;
          -  Understands the study procedures in the informed consent form, and be willing and able&#xD;
             to comply with the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically significant medical or psychiatric condition or&#xD;
             disease&#xD;
&#xD;
          -  History of any illness that might confound the results of the study or poses an&#xD;
             additional risk to the subject by their participation in the study&#xD;
&#xD;
          -  History or presence of alcohol or drug abuse within the past 2 years prior to the&#xD;
             first dosing&#xD;
&#xD;
          -  Females who are nursing, pregnant, or planning to become pregnant while in the study,&#xD;
             and for 30 days after last dose of study drug&#xD;
&#xD;
          -  Positive results at Screening for human immunodeficiency virus (HIV), hepatitis B&#xD;
             surface antigen (HBsAg) or hepatitis C virus (HCV)&#xD;
&#xD;
          -  A positive test or history of incompletely treated or untreated tuberculosis&#xD;
&#xD;
          -  Donation of &gt; 499 mL of blood or plasma within 56 days of Screening (during a clinical&#xD;
             trial or at a blood bank donation) and for 30 days after last dose of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Itraconazole</keyword>
  <keyword>Drug-drug interaction</keyword>
  <keyword>CTP-543</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

